ProfileGDS5678 / 1424619_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 84% 86% 85% 85% 88% 88% 85% 85% 86% 86% 86% 87% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4485386
GSM967853U87-EV human glioblastoma xenograft - Control 26.315284
GSM967854U87-EV human glioblastoma xenograft - Control 36.4752786
GSM967855U87-EV human glioblastoma xenograft - Control 46.5944185
GSM967856U87-EV human glioblastoma xenograft - Control 56.4736585
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6322888
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7065588
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3429285
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3256685
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5113786
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4769486
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5167486
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6141387
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.4822886